Astragalus Immune Function Randomized Trial: What the Evidence Says

Quick Answer

Astragalus Immune Function Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 narrative review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• However, despite the increasing number of studies, current evidence on YPFS remains fragmented and lacks systematic integration. [Gao Shiyu (2026); evidence level 3]
• Further research by Huand Zhaosuggests that YPFS may influence biological processes, including tumor-associated angiogenesis and cell proliferation, by modulating multiple signaling pathways such as AGE-RAGE, IL-17, TNF, and MAPK. [Gao Shiyu (2026); evidence level 3]
• Aging is accompanied by a progressive decline in cellular and organ function, leading to an increased incidence of chronic diseases and neurodegenerative disorders. [Kanubaddi Kiran Reddy (2026); evidence level 4]
• These conditions frequently coexist, and many individuals over the age of 60 present with multiple comorbidities that require combination therapies, which can complicate treatment strategies and increase the risk of drug interactions. [Kanubaddi Kiran Reddy (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For astragalus immune function randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Gao Shiyu (2026). Advances in Yupingfeng San Research: Multi-Target Mechanisms and Clinical Evidence. DOI: 10.2147/DDDT.S603491. PMCID: PMC13196821. PMID: 42182585. License: https://creativecommons.org/licenses/by-nc/4.0/ https://www.dovepress.com/terms.php http://creativecommons.org/licens.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13196821/
• Kanubaddi Kiran Reddy (2026). Astragalus and Cordyceps Derivatives in the Treatment of Aging-Related Chronic Diseases and Neurodegenerative Disorders. DOI: 10.3390/ijms27125273. PMCID: PMC13299804. PMID: 42353002. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13299804/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.